Viveve Medical Inc (NASDAQ:VIVE) Sellers Strengthened By 5.89% Their Shorts As Of Jun 27, 2018

June 27, 2018 - By Ronnie Lemelle

Viveve Medical Inc (NASDAQ:VIVE) noted an increase of 5.89% in shorted shares. FINRA issued in June VIVE’s total 3.33M shorted shares. The up change of 5.89% from 3.14M shares was reported. Viveve Medical Inc (NASDAQ:VIVE) has 281,800 shares average volume. It’ll cost 12 days for VIVE to recover its previous position. Viveve Medical Inc float short is 37.34%.

The stock decreased 0.72% or $0.02 during the last trading session, hitting $2.75.Viveve Medical, Inc. has volume of 152,786 shares. Since June 27, 2017 VIVE has declined 65.48% and is downtrending. VIVE underperformed the S&P 500 by 78.05%.

Viveve Medical, Inc. designs, develops, makes, and markets medical devices for the non-invasive treatment of vaginal laxity.The firm is valued at $85.99 million. The firm offers Geneveve, a non-invasive solution that includes the Viveve System, a radio frequency generator; a reusable hand piece and single-use treatment tip; and other consumable accessories.Last it reported negative earnings. It markets its products through sales employees and distributors in Asia, Europe, the Middle East, Latin America, the United States, Canada, and internationally.

For more Viveve Medical, Inc. (NASDAQ:VIVE) news published recently go to:,,, or The titles are as follows: “Viveve Medical’s CMRF technology shows positive effect in women with SUI; shares up 12% after hours” published on June 18, 2018, “5 Stocks Moving In Monday’s After-Hours Session” on June 19, 2018, “After-Hours Stock Movers 06/18: (GEVO) (VIVE) (CL) Higher; (PAGS) (TELL) (DEA) Lower (more…)” with a publish date: June 18, 2018, “Viveve to Present at Jefferies Global Healthcare Conference” and the last “Viveve Announces Settlement of Patent Infringement Litigation with Thermi” with publication date: June 04, 2018.

Viveve Medical, Inc. (NASDAQ:VIVE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.